

## DAFTAR PUSTAKA

1. Seymour M, Patterson S. Estimating the Prevalence of Chronic Pain in a Given Geographical Area. *J Obs Pain Med.* 2014.
2. Blyth FM, March LM, Brnabic AJM, Jorm LR, Williamson M, Cousins MJ. Chronic pain in Australia: A prevalence study. *Pain.* 2001.
3. Dorland N. *Kamus Kedokteran Dorland.* Jakarta: EGC; 2010.
4. Schug S. Combination analgesia in 2005 - A rational approach: Focus on paracetamol-tramadol. *Clin Rheumatol.* 2006.
5. Pergolizzi J V, van de Laar M, et al. Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. *J Pain Res.*
6. Soenarjo, Eko T, Jatmiko HD, et al. *Buku Kuliah Anestesiologi.* Semarang: Bagian Anestesiologi dan Terapi Intensif Fakultas Kedokteran Universitas Diponegoro; 2015.
7. Samuel SA, Francis AO, Ayomide O. Effects of Paracetamol-Induced Liver Damage on Some Hematological Parameters: Red Blood Cell (RBC) Count, White Blood Cell (WBC) Count, and Packe Cell Volume (PCV) in Wistar Rats of Either Sex. *Indo Am J Pharm Res.* 2015.
8. Scottish Intercollegiate Guidelines Network (SIGN). Control of Pain in Adults with Cancer. *Guidel 106 Control pain adults with cancer.* 2008.
9. Morón Merchante I, Pergolizzi J V, van de Laar M, et al. Tramadol/Paracetamol fixed-dose combination for chronic pain management in family practice: a clinical review. *ISRN Fam Med.* 2013.
10. Yudhowibowo I, Satoto H, Sasongko H. Obat-Obat Anti Nyeri. *J Anestesiol Indones.* 2011.
11. Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. *Pharmacol Reports.* 2009.
12. Sari PM. Pengaruh Pemberian Asetaminofen Berbagai Dosis Peroral Terhadap Gambaran Histopatologi Tubulus Proksimal Ginjal Tikus. *Univ Diponegoro.* 2007.
13. Ferguson M a., Waikar SS. Established and emerging markers of kidney function. *Clin Chem.* 2012.
14. Guyton AC, Hall JE. *Buku Ajar Fisiologi Kedokteran.pdf.* 11th ed. Jakarta: EGC; 2012.

15. Aprioku JS, Nwidu LL, Amadi CN, Aprioku JS. Evaluation of Toxicological Profile of Ibuprofen in Wistar Albino Rats. *Am J Biomed Sci.* 2014.
16. Subekti LW. Pengaruh Pemberian Natrium Diklofenak Dosis 1,4 MG/KgBB dan 2,8 MG/KgBB Terhadap Kadar Ureum Tikus Wistar. 2015.
17. Tallarida RJ, Midic U, Lamarre NS, Obradovic Z. Searching for Synergism Among Combinations of Drugs of Abuse and the Use of Isobolographic Analysis.
18. Aprioku JS, et al. Renal Effects of Non-Steroidal Anti Inflammatory Drugs in Albino Rats.pdf. *Br J Pharm Res.* 2013.
19. Asmadi. *Teknok Prosedural Keperawatan Konsep Dan Aplikasi Kebutuhan Dasar Klien.* Jakarta: Salemba Medika; 2008.
20. Suza DE. Pain Experiences and Pain Management in Postoperative Patients. *Maj Kedokt Nusant.* 2007.
21. Christo PJ, Mazloomdoost D. Cancer pain and analgesia. *Ann N Y Acad Sci.* 2008.
22. Tamsuri A. *Konsep Dan Penatalaksanaan Nyeri.* Jakarta: EGC; 2007.
23. Harahap IA. Pain behavior. *J Keperawatan Rufaidah Sumatera Utara.* 2006.
24. American Academy of Pain Management. *Pain Management: A Practical Guide for Clinicians.* (Weiner RS, ed.). CRC Press; 2001.
25. Prayogi K. Perbandingan Nilai Visual Analog Scale dan efek Samping dari Gabapentin 900 mg dengan Gabapenting 1200 mg Per Oral Sebagai Preemptif Analgesia Pascabedah Dengan Spinal Anestesi. 2015.
26. wongbaker.org. Wong-Baker Pain Rating Scale. [http://wongbakerfaces.org/wp-content/uploads/Double-ScaleFACES\\_English\\_Black.jpg](http://wongbakerfaces.org/wp-content/uploads/Double-ScaleFACES_English_Black.jpg).
27. Butterworth J, Mackey DC, Wasnick J. *Morgan and Mikhail's Clinical Anesthesiology.* McGraw-Hill Education; 2013.
28. Katzung BG, Masters SB, Trevor AJ. *Farmakologi Dasar & Klinik.pdf.* (Soeharsono R, ed.). Jakarta: EGC; 2013.
29. World Health Organization. WHO Three Step Analgesic Ladder.
30. McClellan K, Scott LJ. Tramadol / Paracetamol. 2003;63(11):1079-1086.
31. Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF. The modern pharmacology of paracetamol: Therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. *Inflammopharmacology.* 2013.
32. Smriti Agnihotri TI. Paracetamol Toxicity- An Overview. *Emerg Med Open Access.* 2013.

33. Allegaert K, Rayyan M, De Rijdt T, Van Beek F, Naulaers G. Hepatic tolerance of repeated intravenous paracetamol administration in neonates. *Paediatr Anaesth.* 2008.
34. Fishman S, Ballantyne J, Rathmell JP, eds. *Bonica's Management of Pain*. 4th ed.; 2010.
35. Zyoud SH, Awang R, Syed Sulaiman SA, Al-Jabi SW. Impact of Serum Acetaminophen Concentration on Changes in Serum Potassium, Creatinine and Urea Concentrations Among Patients with Acetaminophen Overdose. *Pharmacoepidemiol Drug Saf*. 2011.
36. Elmanama AA, Abu Tayyem NES, Essawaf HN, Hmaid IM. Tramadol-Induced Liver and Kidney Toxicity among Abusers in Gaza Strip , Palestine. *Jordan J Biol Sci*. 2015.
37. Beakley BD, Kaye AM, Kaye AD. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. *Pain Physician*. 2015.
38. Ajartha R. Efek Pemberian Tramadol Intramuscular Terhadap Nyeri Persalinan Pada Primigravida. 2007.
39. Saleem R, Iqbal R, Abbas MN. Effects of Tramadol on Histopathological and Biochemical Parameters in Mice (*Mus musculus*) Model. *Glob J Pharmacol*. 2014.
40. Minami K, Ogata J, Uezono Y. What is the main mechanism of tramadol? *Naunyn Schmiedebergs Arch Pharmacol*. 2015.
41. Rizzo DC. *Introduction to Anatomy and Physiology*. Delmar; 2011.
42. Saladin. *Human Anatomy*. Internatio. Philippines: McGraw-Hill Education.
43. Hardono S, Andar EB, Adji SR. *Systema Urogenitale*. Semarang: Universitas Diponegoro; 2011.
44. Zhang S-X. *An Atlas of Histology*. Springer; 2013.
45. MH FS, Soejoto, Soetedjo, et al. *Lecture Notes Histologi 2*. Semarang: Universitas Diponegoro; 2011.
46. Sherwood L. *Human Physiology: From Cells to Systems*. Jakarta: EGC; 2012.
47. Koppert W, Frötsch K, Huzurudin N, et al. The effects of paracetamol and parecoxib on kidney function in elderly patients undergoing orthopedic surgery. *Anesth Analg*. 2006.
48. Atici S, Cinel I, Cinel L, Doruk N, Eskandari G, Oral U. Liver and kidney toxicity in chronic use of opioids: an experimental long term treatment model. *J Biosci*. 2005.

49. Faqi AS. *A Comprehensive Guide to Toxicology in Preclinical Drug Development.* (Faqi AS, ed.).
50. Johnson RJ, Freehally J, Floege J. *Comprehensive Clinical Nephrology.* Elsevier; 2014.
51. Marshall WJ, Bangert SK. *Clinical Chemistry.* Elsevier; 2008.
52. Waring WS, Stephen A, Robinson O, Down M, Pettie J. Serum urea concentration and the risk of hepatotoxicity after paracetamol overdose.
53. Laurence D, Bacharach A. *Evaluations of Drug Activities.pdf.* Academic Press; 1964.
54. Sastroasmoro S. *Dasar-Dasar Metodologi Penelitian Klinis.* 5th ed. Jakarta: Sagung Seto; 2014.
55. Kato H. Therapeutic Dose of Acetaminophen as a Possible Risk Factor for Acute Kidney Injury: Learning Afrom Two Healthy Young Adult Cases. *Intern Med.* 2014.
56. Pratiwi H. engaruh Pemberian Paracetamol Berbagai Dosis Terhadap Kadar Kreatinin Dan Blood Urea Nitrogen Pada Tikus Wistar. *Univ Gadjah Mada.* 2015.
57. R Bijak P. Pengaruh Jus Buah Semangka Merah (*Citrullus vulgaris*) Terhadap Kerusakan Sel Ginjal Tikus Putih (*Rattus norvegicus*) Yang Diinduksi Parasetamol. *Univ Sebel Maret.* 2010.
58. Bippi H, Frolich JC. Effects of acetylsalicylic acid and paracetamol alone and in combination on prostanoid synthesis in man. *Br J Clin Pharmacol.* 1990.
59. El-gaafarawi II. Biochemical Toxicity Induced By Tramadol Administration In Male Rats. *Egypt J Hosp Med.* 2006.
60. Essam Hafez M. Parenchymatous Toxicity of Tramadol: Histopathological and Biochemical Study. *J Alcohol Drug Depend.* 2015.
61. Elkhateeb A, El Khishin I, Megahed O, Mazen F. Effect of Nigella sativa Linn oil on tramadol-induced hepato- and nephrotoxicity in adult male albino rats. *Toxicol Reports.* 2015.

## LAMPIRAN

### LAMPIRAN 1. ETHICAL CLEARANCE

|  |
|--|
|  <p>KOMISI ETIK PENELITIAN KESEHATAN (KEPK)<br/>FAKULTAS KEDOKTERAN UNIVERSITAS DIPONEGORO<br/>DAN RSUP dr KARIADI SEMARANG<br/>Sekretariat : Kantor Dekanat FK Undip Lt.3<br/>Jl. Dr. Soetomo 18. Semarang<br/>Telp/Fax. 024-8318350</p>  <p>RSUP DR. KARIADI</p>   |
| <b>ETHICAL CLEARANCE</b><br><b>No. 492/EC/FK-RSDK/2016</b>   |
| <p>Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Diponegoro-RSUP. Dr. Kariadi Semarang, setelah membaca dan menelaah Usulan Penelitian dengan judul :</p> <p><b>"PENGARUH PEMBERIAN ANALGESIK KOMBINASI PARACETAMOL DAN TRAMADOL TERHADAP KADAR UREUM SERUM TIKUS WISTAR"</b></p> <p><b>Peneliti Utama :</b> <i>Intan Ayuningtyas Hapsari</i></p> <p><b>Pembimbing :</b> -dr. Taufik Eko Nugroho, MSi.Med, Sp.An</p> <p><b>Penelitian :</b> Dilaksanakan di Laboratorium Biologi Fakultas MIPA, Universitas Negeri Semarang, Laboratorium Balai Kesehatan Provinsi, Kota Semarang</p> <p>Setuju untuk dilaksanakan, dengan memperhatikan prinsip-prinsip yang dinyatakan dalam Deklarasi Helsinki 1975, yang diamended di Seoul 2008 dan Pedoman Nasional Etik Penelitian Kesehatan (PNEPK) Departemen Kesehatan RI 2011</p> <p>Pada laporan akhir peneliti harus melampirkan cara pemeliharaan &amp; dekapitasi hewan coba dan melaporkan ke KEPK bahwa penelitian sudah selesai dilampiri Abstrak Penelitian.</p> <p style="text-align: right;">Semarang, 27 APR 2016</p> <p style="text-align: right;">Komisi Etik Penelitian Kesehatan<br/>Fakultas Kedokteran Undip-RS. Dr. Kariadi</p> <p style="text-align: right;"><i>Ketua Komisi Etik Penelitian Kesehatan</i><br/><b>Prof. Dr. dr. Suprihati, M.Sc, Sp.THT-KL(K)</b><br/>NIP. 19500621 197703 2 001<br/>RS. DR. KARIADI<br/>SEMARANG</p> |

## LAMPIRAN 2. DATA PENELITIAN

| <b>KELOMPOK</b> | <b>TIKUS KE-</b> | <b>KADAR UREUM<br/>(mg/dl)</b> |
|-----------------|------------------|--------------------------------|
| Kontrol         | 1                | 41,6                           |
|                 | 2                | 47,3                           |
|                 | 3                | 47,7                           |
|                 | 4                | 45,3                           |
|                 | 5                | 45,4                           |
| Perlakuan 1     | 1                | 44,7                           |
|                 | 2                | 45,5                           |
|                 | 3                | 48,9                           |
|                 | 4                | 44,2                           |
|                 | 5                | 50,3                           |
| Perlakuan 2     | 1                | 47,0                           |
|                 | 2                | 49,0                           |
|                 | 3                | 49,4                           |
|                 | 4                | 46,5                           |
|                 | 5                | 44,6                           |
| Perlakuan 3     | 1                | 44,8                           |
|                 | 2                | 47,9                           |
|                 | 3                | 44,3                           |
|                 | 4                | 53,6                           |
|                 | 5                | 41,6                           |

### LAMPIRAN 3. HASIL ANALISIS

**Case Processing Summary**

|       | Kelompok    | Cases |         |         |         |       |         |
|-------|-------------|-------|---------|---------|---------|-------|---------|
|       |             | Valid |         | Missing |         | Total |         |
|       |             | N     | Percent | N       | Percent | N     | Percent |
| Nilai | Kontrol     | 5     | 100.0%  | 0       | 0.0%    | 5     | 100.0%  |
|       | Parasetamol | 5     | 100.0%  | 0       | 0.0%    | 5     | 100.0%  |
|       | Tramadol    | 5     | 100.0%  | 0       | 0.0%    | 5     | 100.0%  |
|       | Parasetamol | 5     | 100.0%  | 0       | 0.0%    | 5     | 100.0%  |
|       | Tramadol    | 5     | 100.0%  | 0       | 0.0%    | 5     | 100.0%  |

**Descriptives**

|       | Kelompok    | Statistic                     | Std. Error  |
|-------|-------------|-------------------------------|-------------|
| Nilai | Kontrol     | Mean                          | 45.460      |
|       |             | 95% Lower Confidence Bound    | 42.461      |
|       |             | Interval for Mean Upper Bound | 48.459      |
|       |             | 5% Trimmed Mean               | 45.550      |
|       |             | Median                        | 45.400      |
|       |             | Variance                      | 5.833       |
|       |             | Std. Deviation                | 2.4152      |
|       |             | Minimum                       | 41.6        |
|       |             | Maximum                       | 47.7        |
|       |             | Range                         | 6.1         |
|       |             | Interquartile Range           | 4.0         |
|       |             | Skewness                      | -1.184 .913 |
|       |             | Kurtosis                      | 1.502 2.000 |
|       | Parasetamol | Mean                          | 46.720      |
|       |             | 95% Lower Confidence Bound    | 43.349      |
|       |             | Interval for Mean Upper Bound | 50.091      |
|       |             | 5% Trimmed Mean               | 46.661      |

|             |                                  |  |        |
|-------------|----------------------------------|--|--------|
|             | Median                           | 45.500   |        |
|             | Variance                         | 7.372  |        |
|             | Std. Deviation                   | 2.7151   |        |
|             | Minimum                          | 44.2   |        |
|             | Maximum                          | 50.3   |        |
|             | Range                            | 6.1  |        |
|             | Interquartile Range              | 5.1  |        |
|             | Skewness                         | .628   | .913   |
|             | Kurtosis                         | -2.341   | 2.000  |
| Tramadol    | Mean                             | 47.300   | .8752  |
|             | 95% Confidence Interval for Mean | Lower Bound<br>44.870<br>Upper Bound<br>49.730 |        |
|             | 5% Trimmed Mean                  | 47.333   |        |
|             | Median                           | 47.000   |        |
|             | Variance                         | 3.830  |        |
|             | Std. Deviation                   | 1.9570   |        |
|             | Minimum                          | 44.6   |        |
|             | Maximum                          | 49.4   |        |
|             | Range                            | 4.8  |        |
|             | Interquartile Range              | 3.7  |        |
|             | Skewness                         | -.336  | .913   |
|             | Kurtosis                         | -1.067   | 2.000  |
| Paracetamol | Mean                             | 46.440   | 2.0505 |
| Tramadol    | 95% Confidence Interval for Mean | Lower Bound<br>40.747<br>Upper Bound<br>52.133 |        |
|             | 5% Trimmed Mean                  | 46.311   |        |
|             | Median                           | 44.800   |        |
|             | Variance                         | 21.023   |        |
|             | Std. Deviation                   | 4.5851   |        |
|             | Minimum                          | 41.6   |        |
|             | Maximum                          | 53.6   |        |
|             | Range                            | 12.0   |        |


|  |                     |       |       |
|--|---------------------|-------|-------|
|  | Interquartile Range | 7.8   |       |
|  | Skewness            | 1.049 | .913  |
|  | Kurtosis            | 1.078 | 2.000 |

### Tests of Normality

|       | Kelompok    | Kolmogorov-Smirnov <sup>a</sup> |    |       | Shapiro-Wilk |    |      |
|-------|-------------|---------------------------------|----|-------|--------------|----|------|
|       |             | Statistic                       | df | Sig.  | Statistic    | df | Sig. |
| Nilai | Kontrol     | .274                            | 5  | .200* | .882         | 5  | .320 |
|       | Parasetamol | .273                            | 5  | .200* | .871         | 5  | .271 |
|       | Tramadol    | .207                            | 5  | .200* | .939         | 5  | .662 |
|       | Parasetamol | .240                            | 5  | .200* | .930         | 5  | .598 |
|       | Tramadol    |                                 |    |       |              |    |      |

\*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction



### ANOVA

Nilai

### Test of Homogeneity of Variances

Nilai

|                | Levene Statistic | df1 | df2         | Sig. |
|----------------|------------------|-----|-------------|------|
|                | 1.515            | 3   | 16          | .249 |
|                | Sum of Squares   | df  | Mean Square | F    |
| Between Groups | 8.860            | 3   | 2.953       | .310 |
| Within Groups  | 152.232          | 16  | 9.514       |      |
| Total          | 161.092          | 19  |             |      |

### Multiple Comparisons

Dependent Variable: Nilai

LSD

| (I) Kelompok | (J) Kelompok | Mean Difference (I-J) | Std. Error | Sig. | 95% Confidence Interval |             |
|--------------|--------------|-----------------------|------------|------|-------------------------|-------------|
|              |              |                       |            |      | Lower Bound             | Upper Bound |
| Kontrol      | Parasetamol  | -1.2600               | 1.9508     | .528 | -5.396                  | 2.876       |
|              | Tramadol     | -1.8400               | 1.9508     | .360 | -5.976                  | 2.296       |
|              | Parasetamol  | -.9800                | 1.9508     | .622 | -5.116                  | 3.156       |
|              | Tramadol     |                       |            |      |                         |             |
| Parasetamol  | Kontrol      | 1.2600                | 1.9508     | .528 | -2.876                  | 5.396       |
|              | Tramadol     | -.5800                | 1.9508     | .770 | -4.716                  | 3.556       |
|              | Parasetamol  | .2800                 | 1.9508     | .888 | -3.856                  | 4.416       |
|              | Tramadol     |                       |            |      |                         |             |
| Tramadol     | Kontrol      | 1.8400                | 1.9508     | .360 | -2.296                  | 5.976       |
|              | Parasetamol  | .5800                 | 1.9508     | .770 | -3.556                  | 4.716       |
|              | Parasetamol  | .8600                 | 1.9508     | .665 | -3.276                  | 4.996       |
|              | Tramadol     |                       |            |      |                         |             |
| Parasetamol  | Kontrol      | .9800                 | 1.9508     | .622 | -3.156                  | 5.116       |
|              | Parasetamol  | -.2800                | 1.9508     | .888 | -4.416                  | 3.856       |
|              | Tramadol     | -.8600                | 1.9508     | .665 | -4.996                  | 3.276       |

**LAMPIRAN 4. DOKUMENTASI PENELITIAN**

## LAMPIRAN 5. BIODATA MAHASISWA

### Identitas

Nama : Intan Ayuningtyas Hapsari  
NIM : 22010112140028  
Tempat/Tanggal Lahir : Jakarta, 6 Desember 1995  
Jenis Kelamin : Perempuan  
Alamat : Perumahan Srondol Bumi Indah, Blok VII/ No 11  
Semarang, Jawa Tengah

### Riwayat Pendidikan Formal

- SD : SD Islam Athirah, Makassar Lulus tahun 2006
- SMP : SMP Negeri 2, Semarang Lulus tahun 2009
- SMA : SMA Negeri 3, Semarang Lulus tahun 2012
- Fakultas Kedokteran  
Universitas Diponegoro, Semarang Masuk tahun 2012

### Keanggotaan Organisasi

1. Himpunan Mahasiswa FK UNDIP, tahun 2012
2. Badan Eksekutif Mahasiswa FK UNDIP, tahun 2013
3. AMSA FK UNDIP, tahun 2013